Analyst Ratings For Abbott Laboratories (NYSE:ABT)
Today, Morgan Stanley raised its price target on Abbott Laboratories (NYSE:ABT) to $85.00 per share.
There are 17 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Abbott Laboratories (NYSE:ABT) is Buy with a consensus target price of $76.2050 per share, a potential 9.29% upside.
Some recent analyst ratings include
- 1/2/2019-Abbott Laboratories (NYSE:ABT) gets downgraded to Sell by Citigroup with a price target of $68.00
- 12/17/2018-Abbott Laboratories (NYSE:ABT) has coverage initiated with a Outperform rating and $82.00 price target
- 12/9/2018-Abbott Laboratories (NYSE:ABT) gets upgraded to Buy by Goldman Sachs Group with a price target of $74.10
- 11/27/2018-Abbott Laboratories (NYSE:ABT) has coverage initiated with a Buy rating and $83.00 price target
- 10/18/2018-Abbott Laboratories (NYSE:ABT) had its In-Line ➝ Buy rating reiterated by Jefferies Financial Group with a $80.00 price target
- On 11/28/2018 Miles D White, Chairman, sold 142,341 with an average share price of $72.35 per share and the total transaction amounting to $10,298,371.35.
- On 11/2/2018 Jared Watkin, Insider, sold 65,000 with an average share price of $71.00 per share and the total transaction amounting to $4,615,000.00.
- On 9/28/2018 Daniel Gesua Sive Salvadori, Insider, sold 5,000 with an average share price of $73.39 per share and the total transaction amounting to $366,950.00.
- On 9/28/2018 Sharon J Bracken, SVP, sold 1,732 with an average share price of $73.35 per share and the total transaction amounting to $127,042.20.
- On 9/20/2018 Brian J Blaser, Insider, sold 58,200 with an average share price of $68.79 per share and the total transaction amounting to $4,003,578.00.
- On 8/29/2018 Andrew H Lane, Insider, sold 9,097 with an average share price of $67.11 per share and the total transaction amounting to $610,499.67.
- On 8/29/2018 Jaime Contreras, SVP, sold 64,268 with an average share price of $66.84 per share and the total transaction amounting to $4,295,673.12.
About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Recent Trading Activity for Abbott Laboratories (NYSE:ABT)
Shares of Abbott Laboratories closed the previous trading session at 69.73 −2.59 3.58% with 69.14 shares trading hands.